IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
- Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of Frank Zaccanelli, Robert K. Coughlin, and Joseph Mangan to its Board of Advisors.
- 04/21/2025
|
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
- POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support enrollment for the CALMA study evaluating IGC-AD1, IGC Pharma's investigational therapy for agitation in Alzheimer's disease, a condition affecting a majority of Alzheimer's patients and significantly impacting caregivers.
- 04/08/2025
|
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
- POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer's dementia, to MIND Institute at Miami Jewish Health in Miami, Florida. This addition further advances the company's efforts to accelerate the trial's completion and builds on promising interim data suggesting the potential of IGC-AD1 to improve patient outcomes.
- 04/01/2025
|
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
- - IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2 sleep disturbance was reduced by about 71% (p=.012) and at week 6 about 78% (p=.02) for those on the active medication.
- 03/26/2025
|
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
- POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and expanding the Company's clinical footprint.
- 03/20/2025
|
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida
- POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia. IGC-AD1 is a combination therapy designed to address agitation in Alzheimer's disease.
- 03/17/2025
|
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
- POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
- 03/12/2025
|
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"
- POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts.
- 03/10/2025
|
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
- POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
- 03/04/2025
|
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
- - New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions. Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships, and targeted influencer marketing and digital advertising.
- 02/20/2025
|
IGC Pharma Reports Third Quarter Fiscal 2025 Results
- POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr.
- 02/18/2025
|
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
- IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
- 02/14/2025
|
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
- - Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic disorders.
- 02/11/2025
|
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
- IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 01/28/2025
|
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
- POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
- 01/28/2025
|
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
- POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery.
- 01/13/2025
|
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
- Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's). The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life for both patients and their caregivers.
- 01/08/2025
|
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
- POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025.
- 12/19/2024
|
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock
- IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/18/2024
|
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment.
- 11/25/2024
|
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
- POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders.
- 11/14/2024
|
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies
- POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies.
- 11/06/2024
|
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
- - Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of Alzheimer's patients and is a major driver of long-term hospitalization, increased mortality, and higher use of medication.
- 10/17/2024
|
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
- POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database. IGC Pharma, Inc. The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National Institutes of Health ("NIH").
- 10/03/2024
|
Nokia deploys high-performance cross-border DWDM network for IGC
- Nokia's Dense Wavelength Division Multiplexing (DWDM) solution was used by IGC to overlay and enhance the existing infrastructure to more effectively manage the growing capacity demand.
- 09/22/2024
|
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment.
- 09/18/2024
|
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease.
- 09/04/2024
|
IGC Pharma Reports First Quarter Fiscal 2025 Results
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports First Quarter Fiscal 2025 Results.
- 08/08/2024
|
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.
- 07/09/2024
|
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease.
- 06/25/2024
|
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for Fiscal Year Ended March 31, 2024.
- 06/24/2024
|
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets.
- 06/18/2024
|
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Publishes Study in European Society of Medicine.
- 06/10/2024
|
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1.
- 05/28/2024
|
IGC Pharma to Attend BIO International Convention 2024
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma to Attend BIO International Convention 2024.
- 05/21/2024
|
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two.
- 04/16/2024
|
IGC Pharma Adds Advisor in Artificial Intelligence
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Adds Advisor in Artificial Intelligence.
- 04/09/2024
|
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock.
- 03/26/2024
|
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation.
- 03/20/2024
|
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024.
- 03/20/2024
|
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma (IGC)- Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline.
- 03/12/2024
|
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Ascendiant Coverage.
- 02/23/2024
|
IGC Pharma Reports Third Quarter Fiscal 2024 Results
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Third Quarter Fiscal 2024 Results.
- 02/16/2024
|
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--TGR-63 Reduces Agitation in Alzheimer's Mouse Model.
- 02/01/2024
|
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Breakthrough - Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's.
- 01/23/2024
|
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial.
- 01/17/2024
|
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's.
- 12/19/2023
|
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.
- 12/13/2023
|
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University's Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treat.
- 12/06/2023
|
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives.
- 11/21/2023
|
IGC Pharma Reports Second Quarter Fiscal 2024 Results
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports Second Quarter Fiscal 2024 Results.
- 11/13/2023
|
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
- POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy.
- 10/19/2023
|
IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate Through Phase 2 Clinical Trials
- POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer's Candidate.
- 08/14/2023
|
IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico
- POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico.
- 08/02/2023
|
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference
- POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer's Association International Conference.
- 07/18/2023
|
IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023
- POTOMAC, MD / ACCESSWIRE / April 18, 2023 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023, at 4:30 PM (Local Time -PDT). Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principal Financial Officer, will be hosting the presentation and answering questions at the conclusion.
- 04/18/2023
|
IGC to Present at the RHK 2022 Disruptive Growth Conference
- POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6.
- 11/30/2022
|
Weed Stocks This Week: Major Earnings Blitz
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 08/12/2022
|
Wheat ETF Surges as Russia-Ukraine War Fuels Supply Concerns
- A wheat-related exchange traded fund surged on Thursday, with wheat futures hitting a 14-year high as Russia's invasion of Ukraine hindered exports from a major global bread basket. Among the best-performing non-leveraged ETFs of Thursday, the Teucrium Wheat Fund (NYSEArca: WEAT) jumped 14.7%.
- 03/03/2022
|
India Globalization Capital Posts Net Loss Of $2.38M For The Third Quarter
- India Globalization Capital, Inc. IGC announced its financial results for the three months ending December 31, 2021 – quarter three of the company's 2022 fiscal year. Q3 Financial Highlights
- 02/11/2022
|
9 Hottest Stories from the Cannabis Sector This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
- 12/10/2021
|
IGC Announces Results of its 2021 Annual Stockholders Meeting
- POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--Voting on all matters as disclosed on the Def Proxy filed with the SEC on Sep 15'21 were passed at IGC's Annual Meeting of Shareholders on Oct 15'21.
- 10/15/2021
|
IGC Stock: Over 15% Increase Pre-Market Explanation
- The stock price of India Globalization Capital, Inc. (NYSEAMERICAN: IGC) increased by over 15% pre-market. This is why it happened.
- 09/08/2021
|
IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability
- POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability.
- 09/07/2021
|
IGC Reports Financial Results for the June 30, 2021, Quarter
- BETHESDA, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC announces financial results for quarter ended Jun 30, 2021 & completion of Phase 1 clinical trial of IGC-AD1 to alleviate Alzheimer's symptoms.
- 08/11/2021
|
India Globalization Capital Receives Patent To Treat Alzheimer's With Cannabis Drug
- India Globalization Capital Receives Patent To Treat Alzheimer's With Cannabis Drug
- 07/23/2021
|
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments
- Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.
- 07/23/2021
|
Why India Globalization Capital Shares Spiked Today
- India Globalization Capital (AMEX:IGC) shares are trading higher after the company announced the issuance of a patent for the treatment of Alzheimer's disease using THC. The company was issued a patent from the United States Patent And Trademark Office titled ‘Ultra-Low Dose THC As A Potential Therapeutic And Prophylactic Agent For Alzheimer's Disease.
- 07/22/2021
|
India Globalization Capital Shares Skyrocket On Receiving Patent For THC Formula To Treat Alzheimer's Disease
- India Globalization Capital, Inc. (AMEX: IGC) revealed Thursday that it has obtained a patent from the United States Patent and Trademark Office for the treatment of Alzheimer's disease. The patent (#11,065,225) is named “ Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's Disease.
- 07/22/2021
|
Highest Volume Penny Stocks to Watch Today? Check These 4 Out
- Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?
- 07/22/2021
|
IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High
- IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis.
- 07/22/2021
|
Top Penny Stocks To Buy Now? 10 To Watch As AMC Volatility Continues
- Which penny stocks are investors watching with AMC back in focus? The post Top Penny Stocks To Buy Now?
- 07/01/2021
|
Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.
- 06/25/2021
|
IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer's Patients
- POTOMAC, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC completed Final Cohort of Phase 1 clinical trial on its THC-based investigational new drug intended to alleviate symptoms of Alzheimer's disease.
- 06/23/2021
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021.
- 06/14/2021
|
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 2 of its Phase 1 Tetrahydrocannabinol (“THC”)-Based Investigational New Drug Clinical Trial on Alzheimer's Patients.
- 06/07/2021
|
India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer's Patients
- 05/14/2021
|
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC got patent (#10,933,082) x its cannabinoid composition & method x treating pain due to Psoriatic Arthritis, Fibromyalgia, Scleroderma & others.
- 03/08/2021
|
Cannabis Earnings: India Globalization Capital Reports Q3 Results
- The bullish conditions over cannabis stocks remain, although momentum has slowed down. International Globalization Capital works in two different sectors, Materials and Health Care (cannabis).
- 02/17/2021
|
IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer's Patients
- POTOMAC, MD--(BUSINESS WIRE)-- #AD--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced that it is enrolling participants suffering from mild to severe dementia due to Alzheimer's disease for its Phase 1 clinical trial. Our subsidiary, IGC Pharma, LLC, received approval from an Institutional Review Board (“IRB”) as previously disclosed, engaged a Principal Investigator and a study site, and began enrolling participants for a Phase 1 trial on its Investigational D
- 11/23/2020
|
IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer's Patients
- POTOMAC, Md.--(BUSINESS WIRE)-- #AD--India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended September 30, 2020, which is the second quarter of its 2021 fiscal year, and the start of Phase 1 cannabinoid-based clinical trial for Alzheimer's Patients. Revenue in the quarter ended September 30, 2020 and September 30, 2019, were $125 thousand and $1,821 thousand, respectively. The decrease in revenue is primarily due to r
- 11/22/2020
|
IGC Reports Financial Results for the Quarter Ended June 30, 2020 While Preparing for Its FDA-Approved Cannabinoid Clinical Trials on Alzheimer’s Patients
- IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients in Puerto Rico.
- 08/19/2020
|
IGC's stock rallies again, after rocketing fourfold on record volume in the previous session
- Shares of India Globalization Capital Inc. surged 26% in premarket trading Thursday, to extend the fourfold rocket ride in the previous session, as they head for an open at the highest level seen during regular-session hours since February 2019. On Wednesday, the stock soared 300.4% on record volume of 333.4 million shares, after the company said it received authorization from the U.S. Food and Drug Administration to initiate a Phase 1 trial of its investigational cannabinoid formulation for the treatment of mile-to-severe dementia resulting from Alzheimer's disease. The FDA did not respond to a request for confirmation. "We are excited with the progress made and that the FDA will allow the Company to initiate trial testing on human subjects using natural organic cannabis extracts," said IGC Chief Executive Ram Mukunda. IGC was in the news in 2018, as the stock soared after the company announced plans for a line of CBD-infused drinks, or those containing cannabinoids. The stock was then delisted from the NYSE American exchange in October 2018, as the exchange said the company had engaged in operations that were "contrary to the public interest." The company said in February 2019 that it successfully challenged the exchange's decision to delist the stock. The stock has rallied more than fivefold (up 433.4%) over the past three months, while the S&P 500 has gained 19.9%.
- 08/13/2020
|
India Globalization Surges On CBD Trial For Alzheimer's
- India Globalization Capital, Inc. (NYSE: IGC) shares are advancing strongly after the company unveiled plans to start an early-stage clinical trial for its cannabinoid, or CBD, formulation.What Happened: Maryland-based Indian Globalization Fund, which operates two business lines, namely infrastructure and life sciences, said late Tuesday the FDA had notified July 30 that it could go ahead with a Phase 1 trial to evaluate its investigational CBD formulation for the treatment of patients suffering from mild-to-severe dementia due to Alzheimer's disease.The company said it plans to begin enrolling patients for a 12-subject safety Multiple Ascending Dose study.In 2017, the company acquired rights to a patent filing by the University of South Florida related to a formulation consisting of ultra-low doses of CBDs combined with other compounds that will likely assist in the treatment of Alzheimer's disease.Following a patent refiling and an additional patent filing, and animal studies, the company held a Pre-IND meeting with the FDA in late 2018. In 2019, the company filed an INDA for a 100-person double blind placebo-controlled trial in Alzheimer's patients.Why It's Important: Alzheimer's disease doesn't have an approved treatment option currently, although there are therapies for alleviating symptoms of the disease.About 5.5 million individuals suffer from Alzheimer's in the U.S. and about 44 million suffer from the disease worldwide, Indian Globalization Fund said, citing data from the Alzheimer's institute.What's Next? The company said it plans to initially conduct trials to establish efficacy of the formulation, codenamed IGC-AD1, on the Behavioral and Psychological Symptoms of Dementia. Eventually, the company plans to evaluate the efficacy of IGC-AD1 on plaques and tangles, characteristics of Alzheimer's.Shares of India Globalization Fund were spiking higher by 59% to $1.02.See more from Benzinga * The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients
- FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients.
- 08/11/2020
|
FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients
- FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients.
- 08/11/2020
|
52 Stocks Moving In Wednesday's Regular-Market Session
- Gainers
Eastman Kodak (NYSE: KODK) shares rose 430.46% to $42.49 during Wednesday's regular session. The market value of their outstanding shares is at $1.8 billion.
Civeo (...
- 07/29/2020
|
IGC Filed a Patent Application with the U.S. Patent Office for a New Formulation to Treat Pain
- IGC filed a patent application with the USPTO for a new cannabinoid formulation intended for treatment of pain in humans and veterinary animals.
- 07/21/2020
|
IGC Receives a Notice of Allowance from the U.S. Patent Office
- IGC received Notice of Allowance from United States Patent & Trademark Office for its cannabinoid formulation to treat seizures in humans & animals.
- 07/20/2020
|
IGC Receives a Notice of Allowance from the U.S. Patent Office
- IGC received Notice of Allowance from United States Patent & Trademark Office for its cannabinoid formulation to treat seizures in humans & animals.
- 07/20/2020
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
- IGC announces its financial results for the Fiscal Year Ended March 31, 2020.
- 07/13/2020
|
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020
- IGC announces its financial results for the Fiscal Year Ended March 31, 2020.
- 07/13/2020
|
Destini wins RM17.4m electrical installation contract
- Destini Bhd has secured a RM17.4 million contract to provide mechanical and electrical (M&E) systems for the GrenePark Village commercial development in Semenyih, Selangor.
- 07/02/2020
|
Three of Azmin Ali's children could not be served with writ of summons in RM329,000 travel bill suit
- Three of Datuk Seri Mohamed Azmin Ali's children were unable to be served with a statement of claim naming them as defendants in their father's case over alleged non-payment of nearly RM329,000 in travel bills incurred by him and his family.
- 07/02/2020
|
Advantage seen for Reservoir Link
- by DASHVEENJIT KAUR/ pic by TMR FILE
ACE Market-bound Reservoir Link Energy Bhd’s fair value (FV) has been estimated at between 47 sen to 52 sen ahead of the oil and gas (O&G) services providers’ listing on July 15 at an offer price of 41 sen per share. Inter-Pacific Research Sdn Bhd stated the company […]
- 07/02/2020
|
Banks’ dividend payout ratio to drop up to 35%
- by ASILA JALIL/ pic by TMR FILE
LOCAL banks’ impaired loans are expected to grow after the six-month loan moratorium ends in September which could lead to a possible drop in dividend payout ratio this year. Fortress Capital Asset Management (M) Sdn Bhd investment advisor and director Geoffrey Ng said non-performing loans may be between […]
- 07/02/2020
|
Kenanga IB appoints Syed Anwar Jamalullail as chairman
- KUALA LUMPUR (July 2): Kenanga Investment Bank Berhad (Kenanga IB) has appointed Tan Sri Syed Zainol Anwar Ibni Syed Putra Jamalullail as its chairman effective July 1. Syed Anwar succeeds Izlan Izhab. In a statement, Kenanga IB managing director Datuk Chay Wai Leong said Syed Anwar’s extensive experience, knowledge and proven leadership will provide the bank the continued momentum to chart innovations, pursue future growth, and further strengthen its position as the largest independent investment bank in the country.
- 07/01/2020
|
Court fixes July 8 to hear Deepak's inter-parte injunction application against Boustead
- KUALA LUMPUR (July 1): The High Court has fixed July 8 to hear carpet businessman Deepak Jaikishian’s application for an inter-parte injunction to bar Boustead Holdings Bhd, its subsidiary Bakti Wira Development Sdn Bhd and four others from engaging in any dealings concerning three plots of land measuring 223 acres in Kapar and Bukit Raja, Selangor.
- 07/01/2020
|
Special Report: Players that embrace tech will be winners in post-Covid-19 era
- AS the world comes to grips with the lifestyle changes wrought by the Covid-19 pandemic, people are talking about the “new normal”. However, GD Express Carrier Bhd’s (GDex) managing director and group CEO Teong Teck Lean thinks it is still premature to determine what the new normal will be for logistics operators.
- 07/01/2020
|
Special Report: Rocky road ahead for logistics operators amid pandemic
- THIS was supposed to be a good year for DHL Express (Malaysia) Sdn Bhd. Volumes were growing at a healthy clip of 6% year on year and it had just invested RM25 million in a new, larger facility in Johor. Then the Covid-19 pandemic broke out and changed everything. “We started off very well. Our volume and revenue were growing. We were ready to take off when the pandemic hit us,” recalls Derek Tully, vice-president of operations of DHL Express.
- 07/01/2020
|
Give us more assistance to recover, FMM requests energy providers
- FMM president Soh Thian Lai says this is necessary to help employers keep their workers during this crucial recovery period.
- 07/01/2020
|
Finding the best way to register a business in Malaysia
- After the big decision to set up a company comes the nitty gritty of how to go about it.
- 06/30/2020
|
SPRM serbu syarikat ketika siasatan projek terowong P Pinang disambung
- SPRM menyerbu 3 syarikat dan ahli politik serta pegawai negeri itu akan disoal siasat.
- 06/30/2020
|
MACC raids companies as probe into Penang tunnel project resumes
- Three companies raided by anti-graft officers, politicians and officials to be questioned.
- 06/30/2020
|
Petra Energy ventures into oilfield operations
- OIL and gas (O&G) outfit Petra Energy Bhd announced last week that its wholly-owned unit Petra Energy Development Sdn Bhd had been awarded a US$40 million (RM170 million) contract from national oil company Petroliam Nasional Bhd (Petronas) for a two-year technical service agreement.
- 06/30/2020
|
Frankly Speaking: Sign of the times
- Last week, Malaysia Building Society Bhd (MBSB) reported a net loss of RM73.25 million for the first quarter ended March 31, 2020, compared with a net profit of RM83.83 million a year earlier, due to higher loan impairments. Alliance Bank Malaysia Bhd also released its numbers for its fourth quarter ended March 31, 2020, which showed net profit falling 12.27% from a year ago, due to higher provision for loan losses. A number of its clients also disclosed problems with their loans.
- 06/29/2020
|
Court to hear the merits of company's challenge against govt's directive on deferring payments
- A Penang-based construction company that is challenging the government's decision that effectively exempted companies from having to pay their creditors for six months, following the imposition of the movement control order (MCO), will get to have its arguments heard in court.
- 06/29/2020
|
Company wins bid for judicial review on 6-month period for debt repayment
- Wabina Constructions & Engineering Sdn Bhd claims the extension of time given by minister Alexander Nanta Linggi is inconsistent with the Companies Act.
- 06/29/2020
|
Malaysian business sentiment improves slightly but stays downbeat for 3Q20 — Dun & Bradstreet
- Business sentiment among Malaysian companies has improved slightly despite remaining in the contractionary zone for the third quarter of 2020, according to Dun & Bradstreet Malaysia's Business Optimism Index study.
- 06/29/2020
|
Developers to launch more projects due to HOC
- Sales in secondary market may improve due to RPGT exemption and lifting of 70% margin of financing limit
by FARA AISYAH/ pic by TMR FILE PROPERTY developers are expected to launch more new developments this year on the back of the reintroduction of the Home Ownership Campaign (HOC). VPC Alliance (KL) Sdn Bhd MD James […]
- 06/29/2020
|
MESF in RM140 mil partnership deal with Dynasty Esports
- This will provide a platform that promotes effective management and control of the esports ecosystem.
- 06/26/2020
|
Property players welcome Penjana initiatives
- On June 5, Prime Minister Tan Sri Muhyiddin Yassin announced a new short-term economic stimulus plan called Pelan Jana Semula Ekonomi Negara, involving 40 initiatives and RM10 billion in direct fiscal injection. Themed “Building the economy together”, Penjana is set to boost the economy, which has been severely affected by the Covid-19 pandemic as well as the subsequent Movement Control Order (MCO) and Conditional MCO (CMCO). The initiatives related to the property market include:
- 06/26/2020
|
Candy maker Khee San engages BDO in financing drawdown probe
- Candy manufacturer Khee San Bhd has engaged the service of BDO Governance Advisory Sdn Bhd to review the validity of Khee San's purchase orders, invoices, and other relevant documents used as a basis to draw down financing from its bankers.
- 06/26/2020
|
Canon embraces new talent for National Camera Day
- by LYDIA NATHAN / pic credit: my.canon
EMBRACING new talent and cultivating a passion for creative photography will be central to the National Camera Day celebration this year, said Canon Marketing (Malaysia) Sdn Bhd. The National Camera Day, which falls on June 29, has long been celebrated globally to pay homage to the existence of […]
- 06/26/2020
|
Datasonic, Axiata, Scomi Energy, MBSB, KUB, Alliance, Widad, Aeon Credit, DRB-Hicom, EcoWorld, Sapura Energy and Anzo
- Based on corporate announcements and news flow today, stocks in focus on Friday (June 26) may include: Datasonic Group Bhd, Axiata Group Bhd, Scomi Energy Services Bhd, Malaysia Building Society Bhd (MBSB), KUB Malaysia Bhd, Alliance Bank Bhd, Widad Group Bhd, Aeon Credit Service (M) Bhd, DRB-Hicom Bhd, Eco World Development Group Bhd, Sapura Energy Bhd and Anzo Holdings Bhd.
- 06/25/2020
|
Widad buys UiTM Seremban 3 campus concessionaire for RM122m
- Widad Group Bhd is acquiring the entire stake in Inovatif Mewah Sdn Bhd (IMSB) – the owner of a concession to develop and maintain the UiTM Seremban 3 campus (US3C) – for RM122 million in cash. The group said its indirect wholly-owned unit, Innovative City Holdings Sdn Bhd, is acquiring IMSB from Menang Development (M) Sdn Bhd, Menang industries (M) Sdn Bhd and Tentu Selesa Sdn Bhd.
- 06/25/2020
|
Deepak files fresh suit against Boustead over 223-acre lands in Selangor
- Carpet businessman Deepak Jaikishan has filed a fresh suit at the High Court here against Boustead Holdings Bhd and its subsidiaries over 223.33 acres of lands in Kapar and Bukit Raja, Selangor.
- 06/25/2020
|
Blue Star Capital investee Dynasty signs 5-year exclusive partnership agreement with Malaysia ESports Federation - DirectorsTalk
- Blue Star Capital plc (LON:BLU), the investing company with a focus on esports, payments, technology and its applications within media and gaming, has provided the following update regarding its investee company Dynasty eSports Pte Ltd. Dynasty has today announced that it has signed a five year exclusive partnership agreement with Malaysia ESports Federation via its ...
- 06/24/2020
|
Advancecon turns to RE for new earnings stream
- by SHAZNI ONG/ pic credit: advancecon.com.my
ADVANCECON Holdings Bhd plans to make headway into renewable energy (RE), as the sector holds high growth potential for the group. The earthwork specialist is in need to diversify its business portfolio which is currently heavily dependent on the construction services, the group’s main revenue contributor since its inception […]
- 06/24/2020
|
Texas Instruments : recognizes 17 suppliers for excellence | MarketScreener
|
AEON Co and AEON BiG management to be placed under one roof
- COME July, the management of AEON Co Ltd’s retail units in Malaysia — AEON Co (M) Bhd and AEON BiG (M) Sdn Bhd — will be restructured and consolidated into a single organisation as part of a 10-year strategy to create an agile, resilient and intrapreneurial retail organisation. The management reorganisation calls for privately held AEON BiG to relocate its offices from Subang Jaya, Selangor, to AEON Co’s headquarters at Taman Maluri, Kuala Lumpur, beginning next month, an internal memorandum sighted by The Edge reveals.
- 06/23/2020
|
Daibochi allocates RM60m for expansion amid strong F&B, FMCG demand
- by ASILA JALIL/ pic credit: daibochi.com
FLEXIBLE packaging solutions provider Daibochi Bhd is setting aside RM60 million to expand capacity as the Covid-19 pandemic continues to drive demand in the group’s key operating segments of food and beverages (F&B) and fast-moving consumer goods (FMCG). The RM60 million expansion is in line with its long-term growth […]
- 06/23/2020
|
Boustead, OCR, GDB, FGV, UEM Sunrise, Vsolar, Ranhill, MBL, Federal International and Permaju
- MPUR (June 19): Based on corporate announcements and news flow today, stocks in focus on Monday (June 22) may include: Boustead Holdings Bhd, OCR Group Bhd, GDB Holdings Bhd, FGV Holdings Bhd, UEM Sunrise Bhd, Vsolar Group Bhd, Ranhill Utilities Bhd, Muar Ban Lee Group Bhd (MBL), Federal International Holdings Bhd and Permaju Industries Bhd.
- 06/19/2020
|
OCR Group associate inks JV to participate in Pahang portion of ECRL
- OCR Group Bhd’s 40%-owned associate company Landasan Surimas Sdn Bhd has entered into a joint-venture (JV) agreement with Perbadanan Kemajuan Negeri Pahang (PKNP) to set up a 70:30 JV named Taraf Raya to provide mechanical and civil works relating to the East Coast Rail Link (ECRL) project within Pahang.
- 06/19/2020
|
Property demand expected to spike on investors’ interest
- The new HOC sees heightened demand particularly for good products and locations that are offered by the more reputable developers, says Knight Frank
by FARA AISYAH/ pic by HUSSEIN SHAHARUDDIN THE short-term National Economic Recovery Plan (Penjana), which includes various incentives that could spur the growth of the property market, has created more space for […]
- 06/19/2020
|
Low valuation, tech adoption may boost M&A activities
- By SHAZNI ONG / Pic by RAZAK GHAZALI
MERGERS and acquisitions (M&A) could be on the rise as businesses are looking for alternatives that would enable them to survive through the tough economic conditions. Players who identify M&A initiatives as part of their long-term growth plans look set to gain a competitive advantage and larger […]
- 06/18/2020
|
MSM’s new liquid sugar product drives growth in exports
- The sugar manufacturer exports about 300 TEUs on a monthly basis now, says CEO
By SHAHEERA AZNAM SHAH MSM Malaysia Holdings Bhd expects global demand for its liquid sugar product to exceed 50,000 tonnes this year and contribute RM100 million to its top line for its financial year 2020. MSM CEO Datuk Khairil Anuar […]
- 06/18/2020
|
MSM eyes higher sugar export
- KUALA LUMPUR (Bernama) -- MSM Malaysia Holdings Bhd (MSM) has secured 200,000 tonnes of sugar products export for this year, said group chief executive officer Datuk Khairil Anuar Aziz.
- 06/17/2020
|
MSM, Eversendai, SCIB, Genting Malaysia, Duopharma, MRCB-Quill REIT and TRC Synergy
- KUALA LUMPUR (June 17): Based on corporate announcements and news flow today, stocks in focus on Wednesday (June 18) may include: MSM Malaysia Holdings Bhd, Eversendai Corp Bhd, Sarawak Consolidated Industries Bhd (SCIB), Genting Malaysia Bhd (GENM), Duopharma Biotech Bhd, MRCB-Quill Real Estate Investment Trust (MQREIT) and TRC Synergy Bhd.
- 06/17/2020
|
Sugar producer MSM eyes profitable FY20
- Sugar producer MSM Malaysia Holdings Bhd aims to make the financial year ending Dec 31, 2020 (FY20) a profitable one, helped by improved efficiency and production capacity at its Johor plant under MSM Sugar Refinery (Johor) Sdn Bhd.
- 06/17/2020
|
Cover Story: Property investors under pressure
- Sleepless nights – that would best describe the mental state of Alex, a property investor, these past few months. He had been optimistic about three years ago when he bought several properties on the advice of a “property guru”. Property prices will go up, you can enjoy bulk discounts and benefit from the rebates now, he was told. He was assured of great options for short or long-term rent to cover the mortgage, plus a lot of cash in hand.
- 06/17/2020
|
Cover Story:New P2P platform offers different approach
- As someone who has spent more than a decade structuring investments for institutional clients, Vincent Soh is used to looking for relatively safe asset classes that still provide a good yield. It also helps that Soh is a risk-averse investor who likes to make carefully informed investment decisions. During that period in his career, Soh realised there were few safe options other than fixed deposits for his clients, which were mostly cash-rich listed companies.
- 06/17/2020
|
Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II
- Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II
- 06/16/2020
|
Bermaz Motor dealerships to start using Petronas Syntium full-synthetic engine oil next month
- Bermaz Auto Bhd has secured the supply of Petronas Syntium full-synthetic engine oil for its Bermaz Motor dealerships after its unit, Bermaz Motor, inked an agreement with Petronas Dagangan Bhd's lubricant arm, Petronas Lubricants Marketing (Malaysia) Sdn Bhd.
- 06/15/2020
|
Hatten Land Q3 net loss widens to RM32.3 million
- CATALIST-LISTED property developer Hatten Land sank deeper into the red in the third quarter, as a spike in expenses added to sales woes from the coronavirus pandemic. Read more at The Business Times.
- 06/15/2020
|
Malaysian online theatre: to pay or not to pay?
- Don’t be a cheapskate: Malaysian online theatre and virtual performing arts events need money to survive.
- 06/14/2020
|
India Globalization Capital, Inc. : annual earnings release | MarketScreener
|
India Globalization Capital, Inc. : publication des résultats annuels | Zone bourse
|
TNB, Iconic Worldwide, AirAsia, KUB, Datasonic, KPJ, BHIC, Muar Ban Lee, AT Systemization, Serba Dinamik and Euro Holdings
- KUALA LUMPUR (June 10): Based on corporate announcements and news flow today, stocks in focus on Thursday (June 11) may include: Tenaga Nasional Bhd (TNB), Iconic Worldwide Bhd, AirAsia Group Bhd, KUB Malaysia Bhd, Datasonic Group Bhd, KPJ Healthcare Bhd, Boustead Heavy Industries Corp Bhd (BHIC), Muar Ban Lee Group Bhd (MBL), AT Systematization Bhd, Serba Dinamik Holdings Bhd and Euro Holdings Bhd.
- 06/10/2020
|
Book industry takes a hit as bookstores close amid MCO
- Retail, book fairs contribute a lot to publishers’ revenue, but due to MCO, textbooks’ tender and supply have been suspended
by NUR HAZIQAH A MALEK/ pic by TMR FILE NOT exempted by the impact of Covid-19 and the Movement Control Order (MCO), news broke last week of bookstores closing in unison. Malaysian Book Publishers Association […]
- 06/09/2020
|
Local skincare brand Safi debuts on Tmall Global
- Malaysian skincare brand Safi has made its debut on e-commerce platform Tmall Global through Lazada’s “Sell to China” programme, which introduces popular Southeast Asian brands to millions of Chinese consumers via cross-border e-commerce. Tmall Global is the largest cross-border e-commerce platform in China, offering Chinese consumers over 25,000 international brands and over 5,100 product categories from 92 countries and regions.
- 06/05/2020
|
Frankly Speaking: Two-and-a-half months is too long
- On May 22, oil and gas (O&G) company Uzma Bhd announced that it had received the requisite approval from national oil company Petroliam Nasional Bhd (Petronas) on the same day to announce that the Tanjong Baram small field risk service contract dated March 27, 2014 — between Petronas and Uzma Energy Ventures (Sarawak) Sdn Bhd, a wholly-owned subsidiary of Uzma, and EnQuest Petroleum Developments Malaysia Sdn Bhd — had been terminated with effect from March 3, 2020. To recap, EnQuest has 70% of the equity interest in the joint venture while Uzma has the remaining 30%.
- 06/02/2020
|
Berjaya Corp, Berjaya Food, Eversendai, K-One, MUI, Parkson, Pintaras Jaya, Sime Darby Plantation and UMW
- Based on corporate announcements and news flow today, companies that may be in focus on Tuesday (June 2) may include: Berjaya Corporation Bhd, Berjaya Food Bhd, Eversendai Corp Bhd, K-One Technology Bhd, Malayan United Industries Bhd, Parkson Holdings Bhd, Pintaras Jaya Bhd, Sime Darby Plantation Bhd and UMW Holdings Bhd.
- 06/01/2020
|
Berjaya Corp to buy home appliances distributor Singer from major shareholder
- Berjaya Corporation Bhd (BCorp), which made a request to suspend trading of its shares, will be taking over home electronic appliances distributor Singer (M) Sdn Bhd, several sources say.
- 06/01/2020
|
Boustead, LYC Healthcare, 7-Eleven, Power Root, BIMB, Vitrox, TIME dotCom, FGV, TNB, Ho Hup, Gadang, Vizione and Cypark
- Based on corporate announcements and news flow today, companies that may be in focus tomorrow (May 29) may include the following: Boustead Holdings Bhd, LYC Healthcare Bhd, 7-Eleven Malaysia Holdings Bhd, Power Root Bhd, BIMB Holdings Bhd, Vitrox Corp Bhd, TIME dotCom Bhd, FGV Holdings Bhd, Tenaga Nasional Bhd, Ho Hup Construction Company Bhd, Gadang Holdings Bhd, Vizione Holdings Bhd and Cypark Resources Bhd.
- 05/28/2020
|
Gadang secures two ECRL work packages worth RM81m
- Gadang Holdings Bhd’s wholly-owned unit Gadang Engineering (M) Sdn Bhd has secured two contracts worth a combined RM81.18 million from China Communications Construction (ECRL) Sdn Bhd in respect of the East Coast Rail Link (ECRL) project.
- 05/28/2020
|
Sunway, Southern Steel, Ann Joo, Tan Chong Motor, Boustead, IOI Corp, KLK, Batu Kawan, MSM, GHL, GDeX, Padini, Ho Hup, BLand and Lambo
- KUALA LUMPUR (May 27): Based on corporate announcements and news flow today, companies in focus tomorrow (May 28) may include: Sunway Bhd, Southern Steel Bhd, Ann Joo Resources Bhd, Tan Chong Motor Holdings Bhd, Boustead Holdings Bhd, IOI Corp Bhd, Kuala Lumpur Kepong Bhd (KLK), Batu Kawan Bhd, MSM Holdings Bhd, GHL Systems Bhd, GD Express Carrier Bhd (GDeX), Padini Holdings Bhd, Ho Hup Construction Company Bhd, Berjaya Land Bhd (BLand) and Lambo Group Bhd.
- 05/27/2020
|
Sanusi dari PAS angkat sumpah MB Kedah
- Adun Jeneri, Muhammad Sanusi Md Nor mengangkat sumpah jawatan di hadapan Sultan Kedah, Sultan Sallehuddin.
- 05/17/2020
|
INDIA GLOBALIZATION CAPITAL, INC. : Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
India Globalization Capital, Inc. Announces Proposed Settlement of Three Derivative Lawsuits and Provides Notice to Shareholders
- IGC announces today proposed settlement of three derivative lawsuits pending since 2018 & 2019 & provides notice to shareholders of the settlement.
- 05/08/2020
|
India Globalization Capital, Inc. Announces Proposed Settlement of Three Derivative Lawsuits and Provides Notice to Shareholders
- IGC announces today proposed settlement of three derivative lawsuits pending since 2018 & 2019 & provides notice to shareholders of the settlement.
- 05/08/2020
|
India Globalization Capitol Shares Spike Higher; Being Mentioned As Possible Face Mask Play
|
Looks like Fiat will never return to Malaysia
- The Fiat brand has departed from Malaysia after recording poor sales in the face of more attractive rival brands.
- 04/01/2020
|
IGC Receives New U.S. Patent to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals
|
IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals
- On Mar 24, USPTO issued a patent for IGC's cannabinoid formulation for the treatment of cachexia & eating disorders in humans & veterinary animals.
- 03/27/2020
|
May 14 hearing of applications by Najib, three others to strike out Deepak’s RM676m suit
- by BERNAMA
The applications by former prime minister Datuk Seri Najib Tun Razak and three others to strike out the RM676 million suit filed by carpet businessman J.R. Deepak Jaikishan will be heard on May 14. Based on information posted on the court website, the hearing is set for today, but it has been vacated to May 14 due to the closure […]
- 03/25/2020
|
Sime Darby Property targets to double recurring income contribution
- We will expand further into industrial and logistic developments to increase recurring income, says acting group CEO
By FARA AISYAH / Pic By XME Business Park Facebook SIME Darby Property Bhd aims to double the recurring income contribution to the company’s earnings in four years. The recurring income segment has contributed about 3% to 4% […]
- 02/28/2020
|
ECRL progress on the right track, says MRL
- The project involves only 30% or about 1,000 Chinese workers from the republic
By AFIQ AZIZ / Pic By MUHD AMIN NAHARUL THE construction progress of East Coast Rail Link (ECRL) is on the right track and not impacted by the Covid-19 outbreak, Malaysia Rail Link Sdn Bhd (MRL) CEO Datuk Seri Darwis Abdul Razak […]
- 02/19/2020
|
Flange Bolt Market Boosting the Growth Worldwide: —…—… Market Key Dynamics, Recent and ...
|
IGC Reports Financial Results for the Quarter Ended December 31, 2019
- IGC announced financial results for the quarter ended December 31, 2019, which is the third quarter of its 2020 fiscal year.
- 02/10/2020
|
India Globalization Capital Subsidiary Holihemp Has Registered A New Trademark "Sunday Soda" For A New CBD Based Beverage
|
CORRECTION: India Globalization Capital Q3 EPS $(0.03)
|
India Globalization Capital More Than Doubles Revenue, Posts Q2 Net Loss of $1.32M
- India Globalization Capital, Inc . (NYSE: IGC ) reported Wednesday with second-quarter revenue of $1.8 million, up 125% from the same quarter in 2018, when it posted $810,000 in revenue. During the quarter, ...
- 11/06/2019
|
India Globalization Cap Q2 EPS $(0.03) Unchanged From $(0.03) YoY, Sales $1.8M Up From $811K YoY
|
IGC Reports Financial Results for the Quarter Ended September 30, 2019
- India Globalization Capital, Inc. today announced financial results for the quarter ended September 30, 2019, which is the second quarter of its 2020 fiscal year.
- 11/06/2019
|
India Globalization Capital reports Q2 results
|
IGC Opens Marketing and Research Hub in Colombia
- India Globalization Capital, Inc. (IGC) announced today that it has opened a marketing and research office in Colombia, South America. Hamsa Biochem SAS, a new beneficially owned subsidiary of IGC, will focus on marketing and research initiatives to advance Hyalolex™, Holi Hemp™, and other products in Latin America and among the greater Hispanic community in the United States, in compliance with applicable law and regulations. Hyalolex™, which is currently available in more than 40 dispensaries in Puerto Rico, is based on a formulation described in a patent filing acquired from the University of South Florida (USF) in 2017, with pre-clinical research that indicates that micro-doses of cannabis, in combination with other natural compounds, may be beneficial to Alzheimer’s cell lines and to memory in transgenic mice.
- 10/04/2019
|
India Globalization Capital Granted Patent Titled 'Method And Composition For Treating CNS Disorders (With THC/CBD)
|
Anavex, Glovia, And India Globalization Capital: The Future Of Alzheimer's Treatments
|
Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, September 20, 2019
|
India Globalization Capital shares are trading higher after the company announced the Institutional Review Board has approved IGC-AD1 for a phase-2 study.
|
IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study
- India Globalization Capital, Inc. (IGC) announced today that the Institutional Review Board (“IRB”), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease. “With this important approval, our Company can implement a 50-person double-blind placebo-controlled trial that we hope begins to prove the efficacy of micro-doses of cannabis in combination with other natural compounds on the behavior of patients suffering from Alzheimer’s. We expect to measure improvements in neuropsychiatric symptoms (“NPI”) such as delusions, agitation/aggression, dysphoria, anxiety, sleep disorder, disinhibition, irritability, apathy and eating abnormalities, among others,” stated Ram Mukunda, CEO.
- 09/19/2019
|
IGC Announces IRB Approval Of IGC-AD1 For Phase-2 study
|
Ola Bola the Musical set to wow audiences in 4 states in Malaysia
- The aim of touring is to allow people from other states to enjoy the show and be reminded of the true spirit of Malaysia
by LYDIA NATHAN/ pic by MUHD AMIN NAHARUL BEGINNING Aug 31, 2019, the awardwinning production of Ola Bola the Musical will tour four states — Penang, Sarawak, Sabah and Pahang — […]
- 08/21/2019
|
Cannabis Stock Gainers, Losers From August 12, 2019
|
India Globalization Cap Q1 EPS $(0.03) Down From $(0.02) YoY, Sales $1.65M Up From $1.478M YoY
|
Cannabis Stock Gainers And Losers From July 29, 2019
|
Lifshitz & Miller LLP Announces Investigation of Amneal Pharmaceuticals, Inc., CareDx, Inc., Casa Systems, Inc., India Globalization Capital, Inc., Just Energy Group Inc., LegacyTexas Financial Group, Inc., Maxar Technologies Inc., and Unum Group
- NEW YORK , July 26, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amneal ...
- 07/26/2019
|
Splitit inks three year deal with GHL
- 22 Jul 2019 - Modern day buy now pay later company, Splitit Payments (ASX:SPT) has today announced a three-year partnership agreement with GHL ePayments Sdn Bhd, part of leading payment service provider, GHL Systems.
- 07/22/2019
|
Cannabis Stocks Gainers And Losers From July 17, 2019
|
Cannabis Stock Gainers And Losers From July 16, 2019
|
Cannabis Stocks Gainers and Losers From July 15, 2019
|
Shares of several cannabis companies are trading lower. The 420 Investor Alan Brochstein attributed weakness to stocks breaking technical support in market where sentiment has been negatively impacted by CannTrust placing hold on product sales.
|
Cannabis Stock Gainers And Losers From July 11, 2019
|
Cannabis Stock Gainers And Losers From July 8, 2019
|
51 Biggest Movers From Yesterday
|
Marijuana Penny Stocks: Where Risk Meets Sin
- Marijuana producers and users, working in a market that's still illegal in many states, are a risky but promising bet for investors.
- 06/25/2019
|
This Marijuana Stock Is Up Almost 300% Since It Announced a CBD-Infused Drink
- Canaccord Genuity predicted that cannabis beverages could outpace general demand for marijuana products by over two times.
- 06/25/2019
|
42 Stocks Moving In Tuesday's Mid-Day Session
|
SDRL, CLDR among premarket gainers
|
India Globalization Cap Q4 EPS $(0.06) Down From $(0.02) YoY, Sales $1.685M Up From $1.142M YoY
|
The Week In Cannabis: Colorado Hits $1B In Sales, Harborside In Canada, Kroger Embraces CBD, And More
|
Week In Review: How Trump's Policies Moved Stocks - June 15 2019
|
India Globalization Capital Subsidiary Secures Hemp Cultivation, Harvesting License In Arizona
|
Malaysia Begins Approving Crypto Exchange Registrations - BlockBoard
- Malaysia’s securities commission has begun registering cryptocurrency exchanges after it started regulating the crypto space earlier this year. The first three crypto trading platform operators have been conditionally approved and given nine months to comply with registration requirements. Meanwhile, 19 crypto exchanges have been told to cease operations. Also read: Indian Supreme Court Postpones Crypto […] .
- 06/05/2019
|
India Globalization Capital Shares Spike Into Positive Territory, Now Up 9%; Traders Circulate World Intellectual Property Organization Doc From European Patent Office For Composition To Treat Seizure Disorders
|
India Globalization Capital Announces 2 Presentation Dates to Support Hyalolex
|
India Globalization Capital Volume Spike on News FDA is Considering a Framework for Marketing of Cannabis
|
71 Biggest Movers From Yesterday
|
India Globalization Capital shares are trading higher after the company announced its Hyalolex cannabinoid-based Alzheimer's therapy will be available in Puerto Rico.
|
'In time for Holi, #holihemp is live https://bit.ly/2UOByTm #hemp #cbd #wholesalecbd $IGC' -Tweet From IGC Twitter Account
|
52 Biggest Movers From Yesterday
|
30 Stocks Moving In Monday's Pre-Market Session
|
62 Biggest Movers From Yesterday
|
50 Stocks Moving In Monday's Mid-Day Session
|
India Globalization Capital Says Expects to Begin Trading on the NYSE American Under Ticker Symbol 'IGC' No Later than Tuesday, February 26, 2019
|
These Are The Biggest Cannabis Bubbles Of 2018
|
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...
|
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action ...
|
UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit ...
|
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...
|
IGCC NOTICE: Rosen Law Firm Reminds India Globalization Capital, Inc. ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...
|
CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages ...
|
INVESTOR ALERT NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit ...
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ...
|
CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages ...
|
What To Do When A Stock You Own Is Halted
|
Week In Review: How Trump's Policies Moved Stocks - Nov. 11, 2018
|
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit ...
|
SHAREHOLDER ALERT: TGTX CPB CHGG ADNT GOOG IGC ALGN SYF RYAAY AQUA: The Law Offices of Vincent ...
|
CLASS ACTION UPDATE for IGC, ALGN and AQUA: Levi & Korsinsky, LLP Reminds Investors of ...
|
A Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. by Gainey and McKenna & Egleston – Blockchain News, Opinion and Jobs
- Blockchain News, Opinion and Jobs – Gainey McKenna & Egleston announced that a class action lawsuit has been filed against India Globalization Capital, Inc. The announcement was made in
- 11/07/2018
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against India ...
|
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against India ...
|
UPDATE: India Globalization Capital Issues Statement On Relisting Of Stock
|
Hearing India Globalization Capital New Symbol Will Be 'IGCC,' Effective Tues., Oct. 30, 2018
|
Short Sellers Are Making Huge Profits In Cannabis Stocks
|
31 Stocks Moving In Thursday's Pre-Market Session
|
56 Biggest Movers From Yesterday
|
58 Biggest Movers From Yesterday
|
Cannabis stocks continue to dip after rallying over past several weeks: India Globalization Capital shares down 12.1%, Tilray Shares Down 10.8%, Canopy Growth shares down 9.6%, Cronos Group shares down 7.4%.
|
45 Stocks Moving In Monday's Mid-Day Session
|
Cannabis-related stocks down after rallying for pas several weeks: Tilray shares down 19.1%, India Globalization Capital shares down 17.0%, Canopy Growth Shares down 13.6%, Cronos shares down 13.6%.
|
